Article
Genetic variation of the IL-28B promoter affecting gene expression.
PloS one - 1 Jan 2011
Sugiyama Masaya, Tanaka Yasuhito, Wakita Takaji, Nakanishi Makoto, Mizokami Masashi
Abstract excerpt
The current standard of care for the treatment of chronic hepatitis C is pegylated interferon-α (PEG-IFNα) and ribavirin (RBV). The treatment achieves a sustained viral clearance in only approximately 50% of patients. Recent whole genome association studies revealed that single nucleotide polymorphisms (SNPs) around IL-28B have been associated with response to the standard therapy and could predict treatment...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
